ET
AXSM icon

Entropy Technologies’s Axsome Therapeutics AXSM Stock Holding History

Entropy Technologies’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.72M Buy
10,171
+1,979
+24% +$342K 0.08% 318
2025
Q4 		$1.5M Buy
+8,192
New +$1.14M 0.08% 303

Other funds holding AXSM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Entropy Technologies's AXSM Position: Q1 2026 in Review

Entropy Technologies increased its Axsome Therapeutics (AXSM) stake by 24% in Q1 2026, buying an estimated $342K and bringing the position to 10,171 shares worth $1.72M. The position accounts for 0.08% of the portfolio, ranked #318.

Entropy Technologies first reported a position in AXSM in Q4 2025 and has held it in 2 quarters since. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

  • Entropy Technologies held 10,171 shares of Axsome Therapeutics worth $1.72M as of Q1 2026.
  • Entropy Technologies bought 1,979 Axsome Therapeutics shares in Q1 2026, an estimated $342K.
  • Axsome Therapeutics made up 0.08% of Entropy Technologies's portfolio in Q1 2026, its #318 holding.
  • Entropy Technologies first reported a position in Axsome Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on Entropy Technologies's 13F filing for Q1 2026, filed 14 May 2026.